Optimizing Novel Therapies and Surgery in Ear...

Dr. Sara Tolaney joins Dr. Monty Pal to discuss optimizing the sequencing and combination of antibody-drug conjugates for metastatic HER2-positive and triple-negative breast cancer, as well as guidelines for managing serious toxicities like ILD and neutropenia. LINK TO FULL TRANS ...  Show more

Myeloma specialists Dr. Marc Braunstein and Dr. Rahul Banerjee join Dr. Monty Pal to discuss recent breakthroughs for patients with multiple myeloma, including expert advice on how to manage side effects and identify the right treatment among a series of novel immuno- and targete ...  Show more

This week’s episode will be focusing on metastatic NSCLC. We will go all the important details on the quickly growing and changing systemic therapy options including traditional chemotherapy, immunotherapy and targeted agents.

For a probing discussion detailing the American Lung Association’s recent 2024 “State of Lung Cancer” report, we are joined by esteemed thoracic medical oncologist Dr. Jacob Sands of Dana-Farber Cancer Institute and Harvard Medical School. Offering insight into actionable targete ...  Show more

This week’s episode will be focusing on early stage and locally advanced non-small cell lung cancer (NSCLC). We will go all the important details on staging, pathology, local and systemic therapy.